CAL02 Low-dose + CAL02 High-dose + Placebo
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia
Conditions
Pneumonia, Pneumococcal Infections
Trial Timeline
Mar 21, 2016 → Feb 20, 2018
NCT ID
NCT02583373About CAL02 Low-dose + CAL02 High-dose + Placebo
CAL02 Low-dose + CAL02 High-dose + Placebo is a phase 1 stage product being developed by Combioxin for Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT02583373. Target conditions include Pneumonia, Pneumococcal Infections.
What happened to similar drugs?
20 of 20 similar drugs in Pneumonia were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02583373 | Phase 1 | Completed |
Competing Products
20 competing products in Pneumonia